January 16, 2024

Following surgery to remove a tumor, patients may have molecular residual disease (MRD), or a small amount of cancer cells that remain in the body but are too small to be detected with imaging. ctDNA, or liquid biopsy, may be used to detect MRD in patients who underwent surgery for colorectal cancer and determine if they will benefit from receiving adjuvant chemotherapy. The research will be presented at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, taking place January 18-20 in San Francisco, California.

January 10, 2024

The latest research exploring innovative approaches for the detection and treatment of prostate, bladder, and kidney cancers will be highlighted in the 2024 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium’s official Press Program. Studies featured in the Press Program are among the more than 700 abstracts that will be presented at the meeting.

January 9, 2024

A new call-to-action published today, January 9, in the journal Cancer details practical steps for the oncology research and clinical care communities to expand access to clinical trials and enable patients to participate closer to their homes.

December 19, 2023

Six studies exploring new approaches for the treatment of gastrointestinal cancers will be highlighted in the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium’s official Press Program. The research includes circulating tumor DNA (ctDNA) in colorectal cancer and new treatment options for pancreatic, liver, and esophageal cancers. Studies featured in the Press Program are among the more than 750 abstracts that will be presented at the Symposium.

December 15, 2023

ASCO has elected Eric J. Small, MD, FASCO, to lead as its President beginning in June 2025. 

December 11, 2023

ConcertAI today announced the acquisition of CancerLinQ, previously a subsidiary of the American Society of Clinical Oncology (ASCO). In conjunction with the acquisition, ASCO will maintain a multi-year cooperation agreement with CancerLinQ. Building on CancerLinQ’s mission when launched by ASCO in 2013, this new venture will enhance and expand CancerLinQ’s use of real-world data, analytics, next-generation AI, and other technologies to improve cancer care and speed clinical research.

November 17, 2023

President Biden announced on Nov. 17, 2023, the appointment of W. Kimryn Rathmell, MD, PhD, Chair of Medicine at Vanderbilt University Medical Center, and Physician-in-Chief for Vanderbilt University Adult Hospital and Clinics, as his choice for director of the National Cancer Institute (NCI).

November 16, 2023

Congress passed a two-tiered continuing resolution (CR) on November 15, 2023, extending FY 2023 federal funding levels until February 2, 2024, for all Department of Health and Human Services agencies, including the National Institutes of Health (NIH) and the National Cancer Institute (NCI). The president is expected to sign the bill.

November 6, 2023

The addition of the T-cell immunoglobulin and ITM domain (TIGIT) inhibitor domvanalimab to the programmed cell death protein 1 (PD-1) inhibitor zimberelimab and chemotherapy may improve outcomes for patients with advanced gastroesophageal cancer. These results will be presented during the November 2023 session of the American Society of Clinical Oncology (ASCO) Plenary Series.

November 6, 2023

A first-in-class antibody-drug conjugate called CMG901 targeting claudin 18.2 (also referred to as CLDN18.2) may be a potential new treatment option for patients with claudin 18.2-positive gastric or gastroesophageal junction cancer. These results will be presented during the November 2023 session of the American Society of Clinical Oncology (ASCO) Plenary Series.

October 24, 2023

Ensuring every patient has access to high-quality, patient-centered, coordinated cancer care is the goal of ASCO Certified, a new program from the Association for Clinical Oncology (ASCO).

October 23, 2023

A new interventional study found that participation in virtual mind-body fitness classes reduced hospitalizations, length of hospital stays, and urgent care visits by half. The research will be presented at the 2023 American Society of Clinical Oncology (ASCO) Quality Care Symposium taking place October 28-29 in Boston. 

October 23, 2023

Patients with head and neck cancer undergoing radiation treatment may experience side effects that can lead to declines in physical functioning and increase healthcare utilization. According to a new study, yoga may help alleviate these negative side effects, especially when family caregivers also participate, and decrease the use of feeding tube placements and emergency department visits. The research will be presented at the 2023 American Society of Clinical Oncology (ASCO) Quality Care Symposium, taking place October 28-29 in Boston.

October 23, 2023

A new study showed that a text-based e-triage program in combination with routine laboratory testing could safely “fast track” patients to treatment with immune checkpoint inhibitors, eliminating the need for an in-person assessment with their doctor, and save patients 66 minutes in total care time and 30 minutes in total wait time per visit to the healthcare center. The research will be presented at the 2023 American Society of Clinical Oncology (ASCO) Quality Care Symposium, taking place October 27-28 in Boston.  

 

October 17, 2023

The American Society of Clinical Oncology and Association for Clinical Oncology (ASCO) are urging members of the Senate Committee on Health, Education, Labor, and Pensions to approve the nomination of Monica M. Bertagnolli, MD, FACS, FASCO, as the next Director of the National Institutes of Health (NIH) during its October 18, 2023, hearing.

Pages